Eprosartan
| Clinical data | |
|---|---|
| Trade names | Teveten |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601237 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 15% (Eprosartan mesylate) |
| Metabolism | not metabolized |
| Elimination half-life | 5 to 9 hours |
| Excretion | Kidney 10%, bile duct 90% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H24N2O4S |
| Molar mass | 424.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.
Eprosartan is sometimes paired with hydrochlorothiazide.
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.